期刊文献+

孟鲁司特联合环索奈德治疗支气管哮喘的临床疗效研究 被引量:5

下载PDF
导出
摘要 目的探讨孟鲁司特联合环索奈德治疗支气管哮喘(哮喘)的临床疗效。方法选取2013年3—9月我院收治的哮喘患者200例,将其随机分为试验组和对照组,各100例。对照组采用环索奈德治疗,试验组在对照组基础上采用孟鲁司特治疗,疗程均为8周。观察两组临床疗效、肺功能指标变化〔第1秒用力呼气末容积(FEV1)、呼气峰值流速(PEFR)〕及不良反应发生情况。结果试验组治疗总有效率为91.0%(91/100),高于对照组的78.0%(78/100)(χ2=11.572,P=0.003)。治疗前两组FEV1、PEFR比较,差异无统计学意义(P>0.05);治疗4、8周后试验组FEV1和PEFR均高于对照组(P<0.05)。两组均未出现明显不良反应。结论孟鲁司特联合环索奈德治疗哮喘疗效确切,无明显不良反应,值得临床推广应用。
出处 《实用心脑肺血管病杂志》 2014年第4期58-59,共2页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
  • 相关文献

参考文献7

二级参考文献44

  • 1傅桂清,田育红,钟耀忠.舒利迭联合孟鲁司特治疗重度哮喘的临床分析[J].实用医学杂志,2007,23(13):2069-2071. 被引量:24
  • 2Leach C. Effect of formulation parameters on hydrofluoroalkanebeclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol, 1999,104(Suppl) : S250-S252.
  • 3Allen DB,Bielory L,Derendorf H, et al. Inhaled corticosteroids : past lessons and future issues. J Allergy Clin Immunol,2003, 112(3 Suppl) :S1-S40.
  • 4Rohatagi S,Derendorf H, Zech K. Risk-benefit value of inhaled corticosteroids: a pharmacokinetic/pharmacodynamic perspective. Chest,2003,123(3 Suppl) :S430-S431.
  • 5Leach CL, Bethke TD, Boudreau RJ, et al. Two-dimensional and 3-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med, 2006,19 : 117-126.
  • 6Newman S, Salmon A, Nave R, et al. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med,2006,100:375-384.
  • 7Leach CL,Davidson PJ, Hasselquist BE, et al. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest,2002,122 : 510-516.
  • 8Agertoft L, Pedersen S. Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children. Am J Respir Crit Care Med, 2003, 168:779-782.
  • 9Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J, 1994,7: 1839-1844.
  • 10Thorsson L, Edsb.acker S, Kallen A, et al. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol,2001,52: 529- 538.

共引文献585

同被引文献67

  • 1慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志(电子版),2014,6(2):67-80. 被引量:2032
  • 2黄英,李艳,刘恩梅,陈坤华,李芙蓉.沙美特罗替卡松联合治疗儿童中重度哮喘的临床研究[J].重庆医科大学学报,2005,30(1):132-135. 被引量:4
  • 3彭秋莹,陈爱欢.白三烯研究进展及其在婴幼儿喘息性疾病中的作用[J].中华儿科杂志,2006,44(7):553-556. 被引量:94
  • 4Philip G,Pedinoff A,Vandormael K,et al.A phase I ran- domized, placebo-controlled,dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma[J].J Asthma, 2010,47 (10) : 1078-1084.
  • 5Global initiative for asthma. Global Strategy For Asthma Management And Prevention[ S]. America, 2011 : 1-124.
  • 6Spears M, Donnelly I, Jolly L, et al. Effect of low-dose theophylline plus beclomethasone on lung function in smokers with asthma: a pilotstudy[J]. Eur Respir J, 2009, 33(5) : 1010-1017.
  • 7Hatzeimann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease [J]. Pulm Pharmaeol Ther, 2010, 23(4) : 235-256.
  • 8Barnes N, Pavord I, Chuchalin A, et al. A randomized, doubleblind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma [ J ]. Clin Exp Allergy, 2012, 42 ( 1 ) : 38-48.
  • 9Pettipher R, Hunter MG, Perkins CM, et al. Heightened response of eosinophilie asthmatic patients to the CRTH2 antagonist 0C000459. Allergy[J]. 2014, 69(9) : 1223-1232.
  • 10Singh D, Cadden P, Hunter M, et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 [J]. EurRespirJ, 2013, 41(1): 46-52.

引证文献5

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部